Tag Archives: arthritis biosimilar

Arthritis Biosimilar for Humira

FDA Approves Third Biosimilar for Arthritis – Amjevita, a Biosimilar to Humira

The U.S. Food and Drug Administration (FDA) on Friday approved the third biosimilar to treat inflammatory types of arthritis – but, like the two that were previously approved, this one will not be available to patients until patent disputes are resolved.
Continue reading FDA Approves Third Biosimilar for Arthritis – Amjevita, a Biosimilar to Humira

Biosimilar For Arthritis Approved

FDA Approves Second Arthritis Biosimilar – Biosimilar Version of Drug Enbrel

The Food and Drug Administration (FDA) has approved etanercept-szzs (brand name: Erelzi), a biosimilar form of etanercept (Enbrel), to treat rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis as well as plaque psoriasis. Earlier this year, infliximab-dyyb (Inflectra), a biosimilar version of infliximab (Remicade), became the first FDA-approved biosimilar for inflammatory types of arthritis in the U.S.
Continue reading FDA Approves Second Arthritis Biosimilar – Biosimilar Version of Drug Enbrel

Akylosing Spodylitis Treatment

FDA Approves First Biosimilar for Arthritis

The U.S. Food and Drug Administration (FDA) has approved Inflectra – a so-called biosimilar version of the biologic Remicade (infliximab) – to treat rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) as well as psoriasis and inflammatory bowel disease. It is the first biosimilar approved in the U.S. for autoimmune, inflammatory conditions, including RA, PsA and AS, and only the second biosimilar approved by the agency to date. (A drug used in cancer treatment, filgrastim-sndz, sold as Zarxio, was approved in March 2015.)
Continue reading FDA Approves First Biosimilar for Arthritis


Arthritis Advocates Achieve More State Legislative Successes

Governor Nathan Deal of Georgia and Governor Bill Haslam of Tennessee have both signed biosimilar legislation into law. Arthritis Foundation Advocates actively lobbied for both bills, meeting with legislators, testifying at hearings, writing letters, making phone calls and working to put patient safety issues associated with biosimilars in front  of the media.

Nathan Deal Bill Signing

The legislation will allow biosimilar medicines to be marketed in these states.  The new laws also require notifying patients and prescribers when biosimilars are dispensed instead of biologics.  Biologics have been vital for people with arthritis – increasing mobility, reducing pain and improving overall quality of life.

Continue reading Arthritis Advocates Achieve More State Legislative Successes